Lp(a)离成为下一个干预靶点还有多远

How far is Lp(a) from becoming the next intervention target?

脂蛋白(a)[Lp(a)]升高是低密度脂蛋白胆固醇(LDL-C)以外的动脉粥样硬化性心血管疾病(ASCVD)的独立危险因素。Lp(a)的致动脉粥样硬化特性与其结构、组分密切相关。然而,关于Lp(a)的检测方法、风险增加切点及起始干预切点、特异性干预手段尚存在诸多困惑。干预Lp(a)是否能带来心血管获益的硬终点研究正在进行。Lp(a)能否成为下一个心血管风险干预靶标值得期待。

Elevated lipoprotein(a)[Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease(ASCVD) other than low-density lipoprotein cholesterol(LDL-C).The atherogenic properties of Lp(a) are closely related to its structure and components.Yet,there remains puzzling issues related to Lp(a) assays,cut-points for increased risk and initial treatment,and specific means of Lp(a) interventions.The endpoint study of whether intervention with Lp(a) results in cardiovascular benefit is in progress.It is anticipated whether Lp(a) will be the next target for cardiovascular risk intervention.